All In Biotech

Free tool

FAERS Monitor: Teflaro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 200327 or its brand name (Teflaro, Ceftaroline Fosamil). Reports on generic versions are filed under their own applications.

Reports

839

Serious

679

81% of reports

Hospitalization

325

Death reported

154

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use141
  • neutropenia77
  • drug ineffective64
  • acute kidney injury52
  • death48
  • rash46
  • agranulocytosis40
  • thrombocytopenia37
  • pyrexia34
  • drug reaction with eosinophilia and systemic symptoms33
  • renal failure31
  • pruritus29
  • toxic epidermal necrolysis27
  • eosinophilia26
  • staphylococcal infection24

Reports by year received

View as table
YearReports
201115
201229
201353
201471
201537
201649
201730
201845
201953
202042
202159
202234
202362
202485
202578
202697

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,320 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
agranulocytosisSignal4054.139.92,028
toxic epidermal necrolysisSignal2744.630.81,108
eosinophiliaSignal2637.325.5881
drug reaction with eosinophilia and systemic symptomsSignal3332.223.0966
staphylococcal infectionSignal2418.212.3375
neutropeniaSignal7714.211.5938
acute kidney injurySignal528.56.5340
thrombocytopeniaSignal378.36.1231
renal failureSignal315.94.1121
off label useSignal1414.03.5333
rashSignal462.62.046
pyrexiaSignal342.51.829
pruritus291.91.312
death481.41.15
drug ineffective641.21.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.